Search

1. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, February 2018

Subject(s):

Clinical Trials as Topic -- standards
Drug Evaluation -- standards
Urinary Bladder Neoplasms -- drug therapy
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

2. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report

Author(s):

Atlas, Steven J., author
Touchette, Daniel R., author
Beinfeld, Molly, author
McKenna, Avery, author
Joshi, Mrinmayee, author
Chapman, Rick M., author
Pearson, Steven D., author
Rind, David M., author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, January 15, 2021

Subject(s):

Antibodies, Monoclonal -- therapeutic use
Urinary Bladder Neoplasms -- drug therapy
Genetic Vectors -- therapeutic use
United States